Compare CNDT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | IVVD |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | 51000 | 122 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.7M | 201.9M |
| IPO Year | 2016 | 2021 |
| Metric | CNDT | IVVD |
|---|---|---|
| Price | $1.55 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 1.1M | ★ 5.2M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,042,000,000.00 | $53,426,000.00 |
| Revenue This Year | $2.01 | $61.57 |
| Revenue Next Year | $4.06 | $41.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $1.15 | $0.49 |
| 52 Week High | $2.98 | $3.07 |
| Indicator | CNDT | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 32.04 |
| Support Level | $1.32 | N/A |
| Resistance Level | $1.61 | $1.01 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 57.86 | 1.81 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation, as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments, namely Commercial Industries, which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas, of which the majority of revenue is generated in the United States.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.